指南与共识支持与姑息治疗

ASCO癌症患者血小板输注临床实践指南更新

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
指南 / 共识 · J Clin Oncol · 2017-11-28

主要推荐:经验丰富中心的自体干细胞移植成人患者可在首次出血时输注而非预防性输注;儿童自体移植及成人/儿童异基因移植仍推荐按阈值预防性输注。其他推荐涉及血液恶性肿瘤、实体瘤、侵入性操作、血小板产品制备、Rh同种免疫预防及输注无效管理。

要点

  • 自体干细胞移植成人患者可在首次出血时输注,而非预防性输注
  • 儿童自体移植及成人/儿童异基因移植仍推荐按阈值预防性输注
  • 其他推荐涵盖血液恶性肿瘤、实体瘤及侵入性操作等场景

核心结论

  • 基于随机对照试验数据,经验丰富中心的自体干细胞移植成人患者可在首次出血时输注血小板,而非预防性输注。

研究设计与样本

  • 更新综述纳入24篇较新文献:3篇临床实践指南、8篇系统综述和13项观察性研究。

主要发现

  • 最重大推荐变化涉及造血干细胞移植中的血小板输注。
  • 儿科自体干细胞移植患者及成人和儿科异基因干细胞移植患者仍推荐在定义的血小板计数阈值进行预防性输注。

关键数值与推荐

  • 自体干细胞移植成人患者可在首次出血时输注血小板,而非预防性输注。
  • 儿童自体移植及成人/儿童异基因移植仍推荐按阈值预防性输注血小板。

临床怎么用

  • 临床可根据患者移植类型和年龄选择血小板输注策略:自体移植成人可出血时输注,儿童自体及异基因移植者按阈值预防性输注。
  • 其他推荐涉及血液恶性肿瘤、实体瘤、侵入性操作、血小板产品制备、Rh同种免疫预防及输注无效管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To provide evidence-based guidance on the use of platelet transfusion in people with cancer. This guideline updates and replaces the previous ASCO platelet transfusion guideline published initially in 2001. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature published from September 1, 2014, through October 26, 2016. This review builds on two 2015 systematic reviews that were conducted by the AABB and the International Collaboration for Transfusion Medicine Guidelines. For clinical questions that were not addressed by the AABB and the International Collaboration for Transfusion Medicine Guidelines (the use of leukoreduction and platelet transfusion in solid tumors or chronic, stable severe thrombocytopenia) or that were addressed partially (invasive procedures), the ASCO search extended back to January 2000. Results The updated ASCO review included 24 more recent publications: three clinical practice guidelines, eight systematic reviews, and 13 observational studies. Recommendations The most substantial change to a previous recommendation involved platelet transfusion in the setting of hematopoietic stem-cell transplantation. Based on data from randomized controlled trials, adult patients who undergo autologous stem-cell transplantation at experienced centers may receive a platelet transfusion at the first sign of bleeding, rather than prophylactically. Prophylactic platelet transfusion at defined platelet count thresholds is still recommended for pediatric patients undergoing autologous stem-cell transplantation and for adult and pediatric patients undergoing allogeneic stem-cell transplantation. Other recommendations address platelet transfusion in patients with hematologic malignancies or solid tumors or in those who undergo invasive procedures. Guidance is also provided regarding the production of platelet products, prevention of Rh alloimmunization, and management of refractoriness to platelet transfusion ( www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki ).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schiffer CA, Bohlke K, Delaney M, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017. PMID: 29182495. doi:10.1200/JCO.2017.76.1734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。